With generic competition for the statin Crestor looming, AstraZeneca Plc has taken steps to increase productivity and narrow its investment focus to three therapeutic areas. Going forward, oncology is a priority for the company followed by medicines for respiratory and cardiovascular and metabolic diseases.
